Gene therapy in regenerative medicine: latest achievements and actual directions of development

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Gene therapy is a group of methods for treatment of various groups of diseases by replacement of damaged, introducing new genes or changing their expression. This is a new and actively developing area in biomedicine. Approaches to regulation of gene therapy drugs at all stages - from production, preclinical and clinical trials, as well as registration and marketing approval are not fully developed and regularly updated. This article provides an overview of worldwide approaches to conducting studies of gene therapy drugs and the procedures for their "accelerated registration”. This article as well summarizes our experience of Lomonosov Moscow State University in development of new direction vectors - gene therapy for the delivery of several therapeutic proteins. In the near future, this approach can be used to increase the effectiveness of gene therapy for stimulating vascular and axon growth, and tissue regeneration.

Full Text

Restricted Access

About the authors

E. A Slobodkina

M.V. Lomonosov Moscow State University


M. N Karagyaur

M.V. Lomonosov Moscow State University

V. Yu Balabanyan

M.V. Lomonosov Moscow State University

P. I Makarevich

M.V. Lomonosov Moscow State University


  1. FDA. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs); Draft guidance for industry. 2018, download.
  2. Hacein-Bey-Abina S., Von Kalle C., Schmidt M. et al. LMO2-associ-ated donal Tcell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302(5644): 415-9.
  3. Cavazzana-Calvo M. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2012; 669(2000): 669-72.
  4. Ginn S.L., Amaya A.K., Alexander I.E. et al. Gene therapy clinical trials worldwide to 2017: An update. J. Gene Med. 2018; 20(5): 1-16.
  5. Liebert M.A. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Gene Med. 2005; 16(9): 1016-27.
  6. Zhang W.W., Li L., Li D. et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum. Gene Ther. 2018; 29(2): 160-79.
  7. EMEA. Summary of product characteristics - Glybera. 2012.
  8. Spark Therapeutics I. LUXTURNA (voretigene neparvovec-rzyl). 2017; 1-16.
  9. EMEA. Summary of product characteristics - Imlygic. 2016.
  10. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug Targets 2018; 18(2): 171-6.
  11. FDA. Summary basis for regulatory action - ZOLGENSMA. 2019.
  12. Червяков Ю.В., Староверов И.Н., Власенко О.Н. и др. Пятилетние результаты лечения больных хронической ишемией нижних конечностей с использованием генной терапии. Ангиология и сосудистая хирургия 2016; 22(4): 38-44.
  13. Deev R.V., Bozo I.Y., Mzhavanadze N.D. et al. PCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia. J. Cardiovasc. Pharmacol. Ther. 2015; 20(5): 473-82.
  14. Deev R., Plaksa I., Bozo I. et al. Results of an international postmarketing surveillance study of pl-VEGF165 safety and efficacy in 210 patients with peripheral arterial disease. Am. J. Cardiovasc. Drugs 2017; 17(3): 235-42.
  15. AnGes. Announces amendment to the global development of HGF plasmid for critical limb ischemia. 2016; 2-3.
  16. EMEA. Strimvelis - summary of product characteristics. 2017.
  17. FDA. Summary basis for regulatory action - Kymriah. 2017.
  18. EMEA. Yescarta - Summary of product characteristics. 2018.
  19. EMEA. Zalmoxis - Summary of product characteristics. 2016.
  20. Shahryari A., Saghaeian Jazi M., Mohammadi S. et al. Development and clinical translation of approved gene therapy products for genetic disorders. Front. Genet. 2019; 10: 868.
  21. Yinglun S.S. Korea cancels approval of gene therapy Invossa for false reporting of ingredient,
  22. Han-soo L. Regulator under fire for neglecting reported side effects of Invossa,23.
  23. Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 № 61-ФЗ (ред. от 06.06.2019). [Federal Law «On the Circulation of Medicines» dated 12.04.2010 № 61-FL (as amended on 06.06.2019)].
  24. Борисов А., Борисова М., Вайпан Д. Комментарий к Федеральному закону от 23 июня 2016 г. № 180-ФЗ «О биомедицинских клеточных продуктах». 2-е изд., доп. и перераб. Москва: Юстицинформ; 2018.
  25. Приказ Минпромторга России от 14.06.2013 № 916 (ред. от 18.12.2015) «Об утверждении правил надлежащей производственной практики». 2015
  26. Росздравнадзор зарегистрировал первый в мире ген-активированный материал для костной пластики. Медвестник 2019,
  27. Деев Р.В., Дробышев А.Ю., Бозо И.Я. и др. Создание и оценка биологического действия ген-активированного остеопластического материала, несущего ген VEGF человека. Клеточная трансплантология и тканевая инженерия 2013; VIII(3): 78-85
  28. FDA. Fast Track. 2018, fast-track-breakthrough-therapy-accelerated-approval-priority-review/ fast-track.
  29. FDA. Breakthrough Therapy, fast-track-breakthrough-therapy-accelerated-approval-priority-review/ breakthrough-therapy.
  30. FDA. Priority Review, priority-review.
  31. FDA. Accelerated Approval, fast-track-breakthrough-therapy-accelerated-approval-priority-review/ accelerated-approval.
  32. FDA. Expedited programs for regenerative medicine therapies for serious conditions. 2019; 17.
  33. Van Norman G.A. Expanding patient access to investigational drugs: single patient investigational new drug and the «Right to try». JACC Basic to Transl. Sci. Elsevier 2018; 3(2): 280-93.
  34. Patrick Celis. Advanced therapy medicinal products (ATMPs) and ATMP Regulation. RD-ACTION, European Medicines Agency, and European Commission-DG SANTE workshop: how European Reference Networks can add value to clinical research; 29 May 2018.
  35. EMA. PRIME: priority medicines, en/human-regulatory/research-development/prime-priority-medicines.
  36. Yano K., Yamato M. Compassionate use and hospital exemption for regenerative medicine: Something wrong to apply the program for patients in a real world. Regen. Ther. Elsevier Taiwan LLC 2018; 8: 63-4.
  37. Kondo H., Hata T., Ito K. et al. The current status of Sakigake designation in Japan, PRIME in the European Union, and Breakthrough Therapy designation in the United States. Ther. Innov. Regul. Sci. 2017; 51(1): 51-4.
  38. Sietsema W.K., Takahashi Y., Ando K. et al. Japan’s conditional approval pathway for regenerative medicines. Regul. Focus 2018; 1-18.
  39. Stone A., Grol M.W., Ruan M.Z.C. et al. Combinatorial Prg4 and Il-1ra gene therapy protects against hyperalgesia and cartilage degeneration in post-traumatic osteoarthritis. Hum. Gene Ther. 2018; 30(2): 225-35.
  40. Betz C., Lenard A., Belting H.G. et al. Cell behaviors and dynamics during angiogenesis. Development 2016; 143: 2249-60.
  41. Карагяур М.Н., Макаревич П.И., Шевченко Е.К. и др. Современные подходы к регенерации периферических нервов после травмы: перспективы генной и клеточной терапии. Гены и Клетки 2017; 12(1): 6-14.
  42. Sulpice E., Ding S., Muscatelli-Groux B. et al. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biology of the Cell 2009; 101(9): 525-39.
  43. Min J.K., Lee Y.M., Jeong H.K. et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-KB pathway. Circ. Res. 2005; 96(3): 300-7.
  44. Makarevich P., Tsokolaeva Z., Shevelev A. et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS One 2012; 7(6): 1-13.
  45. Makarevich P.I., Dergilev K.V., Tsokolaeva Z.I. et al. Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction. PLoS One 2018; 13(5): 1-25.
  46. Karagyaur M., Dyikanov D., Makarevich P. et al. Non-viral transfer of BDNF and uPA stimulates peripheral nerve regeneration. Biomed. Phar-macother. 2015; 74: 63-70.
  47. Kibbe M., Hirsch A., Mendelsohn F. et al. Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther. 2016; 23(3): 306-12.
  48. Kessler J.A., Smith A.G., Cha B.S. et al. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Ann. Clin. Transl. Neurol. 2015; 2(5): 465-78.
  49. Wong E.T., Ngoi S.M., Lee C. Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Ther. 2002; 9: 337-44.
  50. Licursi M., Christian S.L., Pongnopparat T. et al. In vitro and in vivo comparison of viral and cellular internal ribosome entry sites for bicistronic vector expression. Gene Ther. 2011; 18: 631-6.
  51. Qin J.Y., Zhang L., Clift K.L. et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 2010; 5(5): 1-4.
  52. Karagyaur M., Rostovtseva A., Semina E. et al. A bicistronic plasmid encoding brain-derived neurotrophic factor and urokinase plasminogen activator stimulates peripheral nerve regeneration after injury. J. Pharm. Exp. Ther. 2019; 372(3): 248-55.
  53. Moimas S., Novati F., Ronchi G. et al. Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy. Gene Ther. 2013; 20: 1014-21.
  54. Boldyreva M.A., Bondar I.V., Stafeev I.S. et al. Plasmid-based gene therapy with hepatocyte growth factor stimulates peripheral nerve regeneration after traumatic injury. Biomedicine and Pharmacotherapy 2018; 101(5): 682-90.
  55. Pilaro A., Serabian M. Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. 1999: 27: 4-7.
  56. EMA. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. Eur. Med. Agency Guidel. 2018; 44(1): 1-41.

Copyright (c) 2020 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 85657 от 21.07.2023 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies